The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Thierry Facon

Service des Maladies du Sang

Centre Hospitalier Universitaire (CHU)

Lille

France

[email]@chru-lille.fr

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Service des Maladies du Sang, Centre Hospitalier Universitaire (CHU), Lille, France. 2001 - 2009
  • Service des Maladies du Sang, Hôpital Claude Huriez, CHU, rue Michel Polonovski, 59037 Lille Cedex, France. 2006 - 2009

References

  1. Frontline treatment in elderly patients with multiple myeloma. Facon, T., San Miguel, J., Mateos, M.V., Hulin, C. Semin. Hematol. (2009) [Pubmed]
  2. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Facon, T., Mary, J.Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J.L., Guillerm, G., Chaleteix, C., Dib, M., Voillat, L., Maisonneuve, H., Troncy, J., Dorvaux, V., Monconduit, M., Martin, C., Casassus, P., Jaubert, J., Jardel, H., Doyen, C., Kolb, B., Anglaret, B., Grosbois, B., Yakoub-Agha, I., Mathiot, C., Avet-Loiseau, H. Lancet (2007) [Pubmed]
  3. Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Facon, T., Darre, S. Best. Pract. Res. Clin. Haematol (2007) [Pubmed]
  4. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Facon, T., Mary, J.Y., Pégourie, B., Attal, M., Renaud, M., Sadoun, A., Voillat, L., Dorvaux, V., Hulin, C., Lepeu, G., Harousseau, J.L., Eschard, J.P., Ferrant, A., Blanc, M., Maloisel, F., Orfeuvre, H., Rossi, J.F., Azaïs, I., Monconduit, M., Collet, P., Anglaret, B., Yakoub-Agha, I., Wetterwald, M., Eghbali, H., Vekemans, M.C., Maisonneuve, H., Troncy, J., Grosbois, B., Doyen, C., Thyss, A., Jaubert, J., Casassus, P., Thielemans, B., Bataille, R. Blood (2006) [Pubmed]
  5. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laï, J.L., Leleu, X., Jouet, J.P., Bauters, F., Harousseau, J.L., Bataille, R., Mary, J.Y. Blood (2001) [Pubmed]
 
WikiGenes - Universities